Figure 1.

PI3K is a potential therapeutic target in PTCL. (A) Connectivity Map identified PI3K/mTOR pathway inhibitors (indicated by arrows) as the drugs that could potentially reverse (negative enrichment score) the PTCL molecular signature in a very significant manner. (B) The GSEA program revealed that three survival pathways [T-cell receptor (TCR), NF-κB and CD40 signaling] were positively and significantly (false discovery rate <0.25) correlated with PIK3CD expression in the PTCL molecular signature. (C and D) Both PIK3CA and PIK3CD genes were overexpressed in (C) PTCL and CTCL cell lines and (D) Sézary's syndrome (SS) primary T cells compared with normal T cells isolated from healthy donors (control #1-3) measured by quantitative RT-PCR.